New FDA Approval for Relapsed/Refractory HER2-Positive Metastatic Breast Cancer

​The FDA has now granted accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu®, Daiichi Sankyo) for patients with unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-positive breast cancer previously treated with at least two anti-HER2–based regimens in the metastatic setting. Fam-trastuzumab deruxtecan-nxki, otherwise known as trastuzumab deruxtecan, is an antibody-drug conjugate consisting of an anti-HER2 antibody, a cleavable tetrapeptide-based linker, and a...
Continue reading

Enfortumab Vedotin Approved for Urothelial Carcinoma

​The FDA has approved enfortumab vedotin (Padcev®, Astellas Pharma US, Inc.) for patients with locally advanced or metastatic urothelial carcinoma. Enfortumab vedotin is indicated for patients whose disease progressed after prior treatment with platinum-based chemotherapy and anti–programmed cell death protein 1 (anti–PD-1) or anti–programmed death ligand 1 (anti–PD-L1) therapy. Enfortumab vedotin targets Nectin-4, a cell adhesion molecule highly expressed in urothelial cancers, and is the first...
Continue reading

Prescribing a Healthy Diet and Exercise for Breast Cancer With Neil Iyengar, MD

Patients with breast cancer can derive significant benefits from eating well and staying physically active during their treatment. In his previous interview with i3 Health, Neil Iyengar, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, explained the roles that nutrition and exercise can play in the prevention and treatment of breast cancer. In this second installment, Dr. Iyengar discusses the personalized strategies that are most likely to benefit patients. In addition, he of...
Continue reading

Nutrition and Exercise Before, During, and After Breast Cancer With Neil Iyengar, MD

Proper nutrition and adequate exercise can be considerably effective not only in helping to relieve symptoms and enhance quality of life in patients who have been diagnosed with breast cancer, but also to possibly prevent the development and progression of breast and other cancers. Neil Iyengar, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, has performed extensive research regarding the link between metabolic health and the development and recurrence of breast cancer, a top...
Continue reading

Floxuridine Plus Gemcitabine and Oxaliplatin: Promising Results for Unresectable IHC

With a median overall survival of only 11 months, intrahepatic cholangiocarcinoma (IHC) warrants more effective therapies. Researchers recently discovered that a regimen of hepatic arterial infusion of floxuridine plus systemic gemcitabine and oxaliplatin produces promising outcomes in patients with unresectable IHC.In this phase 2 clinical trial, 38 patients with histologically confirmed, unresectable IHC were enrolled and treated. Participants with resectable metastatic disease to regional lym...
Continue reading

Copyright © 2020 i3 Health. All rights reserved.